These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 18324928

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 3. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lipid management in the geriatric patient.
    Nair AP, Darrow B.
    Endocrinol Metab Clin North Am; 2009 Mar 22; 38(1):185-206. PubMed ID: 19217519
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Management of dyslipidemia in diabetes.
    Solano MP, Goldberg RB.
    Cardiol Rev; 2006 Mar 22; 14(3):125-35. PubMed ID: 16628021
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J.
    Diabetes Obes Metab; 2007 Sep 22; 9(5):609-16. PubMed ID: 17697054
    [Abstract] [Full Text] [Related]

  • 11. Fenofibrate: treatment of hyperlipidemia and beyond.
    Rosenson RS.
    Expert Rev Cardiovasc Ther; 2008 Nov 22; 6(10):1319-30. PubMed ID: 19018684
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination statin-fibrate therapy: safety aspects.
    Franssen R, Vergeer M, Stroes ES, Kastelein JJ.
    Diabetes Obes Metab; 2009 Feb 22; 11(2):89-94. PubMed ID: 18518891
    [Abstract] [Full Text] [Related]

  • 15. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P.
    Am J Manag Care; 2009 Mar 22; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W.
    MMW Fortschr Med; 2005 Apr 07; 147(14):14. PubMed ID: 15887675
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV, Frick KD, Wade A, Simko R, Burge R.
    Clin Ther; 2009 Apr 07; 31(4):862-79. PubMed ID: 19446159
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.